FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200364458> ?p ?o ?g. }

• W4200364458 endingPage "24" @default.
• W4200364458 startingPage "14" @default.
• W4200364458 abstract "Polatuzumab vedotin-bendamustin-rituximab (PBR) and tafasitamab-lenalidomide (Tafa-L) were approved recently for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in autologous stem cell transplant (ASCT) ineligible patients. We performed an industry-independent pharmacoeconomic evaluation of both regimens over a 5-year (y) time horizon (US payer perspective; 2020 USD).Survival curves, treatment costs, and utility values were applied in a three-state Markov model (progression-free survival (PFS), post-progression survival (PPS), death) to estimate the incremental follow-up (ICER) and cost-utility ratios (ICUR). A novel metric of the incremental cost per 1% gain in the probability of achieving objective response (OR), PFS, and OS were estimated.Five-year Tafa-L costs ($470,119) exceeded PBR's ($249,217) by $220,902 with incremental gains of 0.71 life-years (LY) and 0.32 quality-adjusted life-years (QALY); yielding ICER of $310,041/LYg and ICUR of $694,241/QALYg. Tafa-L had favorable PFS and OS rates over PBR with adjusted differences of +19.2 and +34.1%, respectively at trial follow-up (∼2 years), with corresponding 5 years differences in survival of +7.8% in PFS and +21.4% in OS. The incremental cost per 1% gain in the probability of achieving OR, PFS and OS at follow-up were $8,479, $6,359, and $3,583; and $28,321 and $10,323 for PFS and OS at 5 years.The sustained Tafa-L treatment demonstrated better survival outcomes than 6-cycle PBR though at a greater cost. The incremental costs to gain a 1% improvement in 2 and 5 years survival outcomes with Tafa-L over PBR were modest, underscoring the longer-term benefit of Tafa-L over PBR in patients ineligible for or opting out of ASCT.PLAIN LANGUAGE SUMMARYTwo new medication regimens were approved recently for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL): six cycles of polatuzumab vedotin-bendamustine-rituximab (PBR) and continuous twice-monthly treatment with tafasitamab-lenalidomide (Tafa-L). Both treatments are expensive, but Tafa-L more so because it requires continuous treatment versus the maximum 6 cycles of PBR. However, Tafa-L may have better progression-free (PFS) and overall survival (OS) outcomes. Is this worth the additional money?We conducted a cost-effectiveness analysis comparing Tafa-L to PBR. After calculating the differenced in costs and the progression-free and overall survival, we determined the additional cost to gain a life year (LY) or quality-adjusted life year (QALY) over 5 years. We also introduced a novel metric: how much it would cost extra to gain, with Tafa-L treatment, an improvement in progression-free or overall survival of 1% over the survival afforded by PBR. Treatment with Tafa-L over PBR would cost an extra $220,902 for a gain of 0.71 life years (standardized, $310,041/LYgained) and 0.32 quality-adjusted life years ($694,241/QALYgained). Importantly, two years of Tafa-L treatment increased the likelihood of progression-free survival by +19.2% and overall survival by 34.1% over PBR; extending to +7.8% in progression-free survival and +21.4% in overall survival at five years. It cost an additional $28,321 per 1% gain in likelihood in progression-free survival and $10,323 per 1% gain in overall survival after 5 years. Summarized, the increased costs of Tafa-L translate into significantly better progression-free and overall survival." @default.
• W4200364458 created "2021-12-31" @default.
• W4200364458 creator A5002479254 @default.
• W4200364458 creator A5030975381 @default.
• W4200364458 creator A5049387929 @default.
• W4200364458 date "2021-11-16" @default.
• W4200364458 modified "2023-09-30" @default.
• W4200364458 title "Economic evaluation of polatuzumab-bendamustine-rituximab <i>vs.</i> tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL" @default.
• W4200364458 cites W1049067418 @default.
• W4200364458 cites W1552366432 @default.
• W4200364458 cites W1992538067 @default.
• W4200364458 cites W2024001130 @default.
• W4200364458 cites W2027774332 @default.
• W4200364458 cites W2058056848 @default.
• W4200364458 cites W2117419474 @default.
• W4200364458 cites W2134047636 @default.
• W4200364458 cites W2150587745 @default.
• W4200364458 cites W2744261860 @default.
• W4200364458 cites W2798010797 @default.
• W4200364458 cites W2809572695 @default.
• W4200364458 cites W2883371432 @default.
• W4200364458 cites W2921072067 @default.
• W4200364458 cites W2970333266 @default.
• W4200364458 cites W2984927918 @default.
• W4200364458 cites W3034162969 @default.
• W4200364458 cites W3090445859 @default.
• W4200364458 doi "https://doi.org/10.1080/13696998.2021.2007704" @default.
• W4200364458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34866523" @default.
• W4200364458 hasPublicationYear "2021" @default.
• W4200364458 type Work @default.
• W4200364458 citedByCount "3" @default.
• W4200364458 countsByYear W42003644582021 @default.
• W4200364458 countsByYear W42003644582023 @default.
• W4200364458 crossrefType "journal-article" @default.
• W4200364458 hasAuthorship W4200364458A5002479254 @default.
• W4200364458 hasAuthorship W4200364458A5030975381 @default.
• W4200364458 hasAuthorship W4200364458A5049387929 @default.
• W4200364458 hasBestOaLocation W42003644581 @default.
• W4200364458 hasConcept C112930515 @default.
• W4200364458 hasConcept C126322002 @default.
• W4200364458 hasConcept C143998085 @default.
• W4200364458 hasConcept C2776063141 @default.
• W4200364458 hasConcept C2776364478 @default.
• W4200364458 hasConcept C2776694085 @default.
• W4200364458 hasConcept C2778559949 @default.
• W4200364458 hasConcept C2779338263 @default.
• W4200364458 hasConcept C2779900020 @default.
• W4200364458 hasConcept C2780653079 @default.
• W4200364458 hasConcept C2780739268 @default.
• W4200364458 hasConcept C2781442060 @default.
• W4200364458 hasConcept C3019080777 @default.
• W4200364458 hasConcept C3019894029 @default.
• W4200364458 hasConcept C64332521 @default.
• W4200364458 hasConcept C71924100 @default.
• W4200364458 hasConceptScore W4200364458C112930515 @default.
• W4200364458 hasConceptScore W4200364458C126322002 @default.
• W4200364458 hasConceptScore W4200364458C143998085 @default.
• W4200364458 hasConceptScore W4200364458C2776063141 @default.
• W4200364458 hasConceptScore W4200364458C2776364478 @default.
• W4200364458 hasConceptScore W4200364458C2776694085 @default.
• W4200364458 hasConceptScore W4200364458C2778559949 @default.
• W4200364458 hasConceptScore W4200364458C2779338263 @default.
• W4200364458 hasConceptScore W4200364458C2779900020 @default.
• W4200364458 hasConceptScore W4200364458C2780653079 @default.
• W4200364458 hasConceptScore W4200364458C2780739268 @default.
• W4200364458 hasConceptScore W4200364458C2781442060 @default.
• W4200364458 hasConceptScore W4200364458C3019080777 @default.
• W4200364458 hasConceptScore W4200364458C3019894029 @default.
• W4200364458 hasConceptScore W4200364458C64332521 @default.
• W4200364458 hasConceptScore W4200364458C71924100 @default.
• W4200364458 hasIssue "sup1" @default.
• W4200364458 hasLocation W42003644581 @default.
• W4200364458 hasLocation W42003644582 @default.
• W4200364458 hasOpenAccess W4200364458 @default.
• W4200364458 hasPrimaryLocation W42003644581 @default.
• W4200364458 hasRelatedWork W2416082333 @default.
• W4200364458 hasRelatedWork W2892108064 @default.
• W4200364458 hasRelatedWork W2943663841 @default.
• W4200364458 hasRelatedWork W3029631621 @default.
• W4200364458 hasRelatedWork W3091900725 @default.
• W4200364458 hasRelatedWork W3172476911 @default.
• W4200364458 hasRelatedWork W3194854948 @default.
• W4200364458 hasRelatedWork W4310114227 @default.
• W4200364458 hasRelatedWork W4365145352 @default.
• W4200364458 hasRelatedWork W4383873053 @default.
• W4200364458 hasVolume "24" @default.
• W4200364458 isParatext "false" @default.
• W4200364458 isRetracted "false" @default.
• W4200364458 workType "article" @default.